Protagonist Therapeutics

PTGX | NASDAQ | 0 Obserwujący

$50.21

-9.16%

-$5.06

Obserwuj

Overview Metrics Financials

Fair Price

$68.43

Overvalued by 80.7%

Aby wyświetlić sprawiedliwą cenę akcji, musisz być członkiem Bulios Black.

Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing peptide-based therapeutics for hematological disorders and inflammatory diseases. Their lead candidate, rusfertide, is a synthetic mimetic of the hormone hepcidin, currently in Phase 3 clinical trials for the treatment of polycythemia vera, a rare blood disorder. In 2024, the company entered into an agreement with Takeda Pharmaceutical, receiving an upfront payment of $300 million for global commercialization rights to rusfertide outside the U.S.

Feed

There are no posts to show right now.

Protagonist Therapeutics

Fair Price

Profile

Feed

Zaloguj się do Bulios

Utwórz profil Bulios

Dlaczego Bulios?